SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection 10 mL

Name: Monoclonal Antibody
Brand: SKYRIZI®

SKYRIZI, SDV 600MG/10ML D/S

McKesson #

1212567

Manufacturer #

00074501501

Brand

SKYRIZI®

Manufacturer

AbbVie US LLC

Country of Origin

Unknown

Application

Monoclonal Antibody

Container Type

Single-Dose Vial

Dosage Form

Injection

Generic Drug Code

52473

Generic Drug Name

Risankizumab-rzaa

NDC Number

00074501501

Product Dating

McKesson Acceptable Dating: we will ship >= 180 days

Storage Requirements

Requires Refrigeration

Strength

60 mg / mL

Type

Intravenous

UNSPSC Code

42142619

Volume

10 mL

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
600 mg/10 mL (60 mg/mL) single-dose vial